{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T21:32:57Z","timestamp":1786397577408,"version":"build-2736575974"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,11,10]],"date-time":"2022-11-10T00:00:00Z","timestamp":1668038400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,11,10]],"date-time":"2022-11-10T00:00:00Z","timestamp":1668038400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004359","name":"Vetenskapsr\u00e5det","doi-asserted-by":"publisher","award":["2021-01187"],"award-info":[{"award-number":["2021-01187"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002794","name":"Cancerfonden","doi-asserted-by":"publisher","award":["CAN2017\/340"],"award-info":[{"award-number":["CAN2017\/340"]}],"id":[{"id":"10.13039\/501100002794","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009736","name":"Allm\u00e4nna Sjukhusets i Malm\u00f6 Stiftelse f\u00f6r Bek\u00e4mpande av Cancer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009736","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003252","name":"Lund University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003252","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Individuals with a family history of colorectal cancer (CRC) are at a high risk of developing CRC. Preclinical studies suggest that the anti-malaria drug proguanil and atovaquone might play a role in preventing CRC, but population-based evidence is still lacking.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>By accessing a couple of nationwide Swedish registers, we performed a cohort study to explore whether using proguanil and atovaquone might associate with a lower risk of CRC by adopting a new-user study design. Adults who have 1 or more first-degree relatives (parents or siblings) diagnosed with CRC were identified and linked with the Prescribed Drug Register to evaluate their administration history of proguanil and atovaquone. Survival analysis of the time to CRC diagnosis with Cox proportional hazards regression was used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 16,817 incident proguanil\/atovaquone users were identified and matched with 168,170 comparisons, who did not use proguanil\/atovaquone, on the ratio of 1:10. We found a significant negative association between proguanil\/atovaquone use and risk of CRC (adjusted HR, 0.76; 95% CI, 0.62\u20130.93). Test for trend showed significant dose- and duration-response correlations (<jats:italic>P<\/jats:italic>&lt; 0.001). The association was more pronounced in CRC diagnosed at an advanced stage than at an early stage (adjusted HR, 0.69 vs.0.81).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>This national-wide population-based cohort study showed that the use of proguanil and atovaquone was associated with a reduced risk of CRC among individuals with a family history of CRC.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s12916-022-02643-3","type":"journal-article","created":{"date-parts":[[2022,11,10]],"date-time":"2022-11-10T13:03:03Z","timestamp":1668085383000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Proguanil and atovaquone use is associated with lower colorectal cancer risk: a nationwide cohort study"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0668-7822","authenticated-orcid":false,"given":"Naiqi","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Sundquist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina","family":"Sundquist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianguang","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,10]]},"reference":[{"issue":"6","key":"2643_CR1","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394\u2013424.","journal-title":"CA Cancer J Clin"},{"key":"2643_CR2","doi-asserted-by":"crossref","unstructured":"Global Burden of Disease Cancer C, Fitzmaurice C, Abate D, Abbasi N, Abbastabar H, Abd-Allah F, et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2017: a systematic analysis for the global burden of disease study. JAMA Oncol. 2019;5(12):1749\u201368.","DOI":"10.1001\/jamaoncol.2019.2996"},{"issue":"7264","key":"2643_CR3","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1136\/bmj.321.7264.805","volume":"321","author":"P Boyle","year":"2000","unstructured":"Boyle P, Langman JS. ABC of colorectal cancer: epidemiology. BMJ. 2000;321(7264):805\u20138.","journal-title":"BMJ."},{"issue":"2","key":"2643_CR4","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1056\/NEJM200007133430201","volume":"343","author":"P Lichtenstein","year":"2000","unstructured":"Lichtenstein P, Holm NV, Verkasalo PK, Iliadou A, Kaprio J, Koskenvuo M, et al. Environmental and heritable factors in the causation of cancer--analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med. 2000;343(2):78\u201385.","journal-title":"N Engl J Med"},{"issue":"10","key":"2643_CR5","doi-asserted-by":"publisher","first-page":"2992","DOI":"10.1111\/j.1572-0241.2001.04677.x","volume":"96","author":"LE Johns","year":"2001","unstructured":"Johns LE, Houlston RS. A systematic review and meta-analysis of familial colorectal cancer risk. Am J Gastroenterol. 2001;96(10):2992\u20133003.","journal-title":"Am J Gastroenterol"},{"issue":"6","key":"2643_CR6","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1007\/s10552-013-0201-5","volume":"24","author":"CM Johnson","year":"2013","unstructured":"Johnson CM, Wei C, Ensor JE, Smolenski DJ, Amos CI, Levin B, et al. Meta-analyses of colorectal cancer risk factors. Cancer Causes Control. 2013;24(6):1207\u201322.","journal-title":"Cancer Causes Control"},{"issue":"2","key":"2643_CR7","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1111\/j.1365-2796.2011.02399.x","volume":"270","author":"M Bretthauer","year":"2011","unstructured":"Bretthauer M. Colorectal cancer screening. J Intern Med. 2011;270(2):87\u201398.","journal-title":"J Intern Med"},{"key":"2643_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2021.113378","volume":"219","author":"D Kathuria","year":"2021","unstructured":"Kathuria D, Raul AD, Wanjari P, Bharatam PV. Biguanides: species with versatile therapeutic applications. Eur J Med Chem. 2021;219:113378.","journal-title":"Eur J Med Chem"},{"key":"2643_CR9","doi-asserted-by":"publisher","first-page":"191","DOI":"10.3389\/fendo.2020.00191","volume":"11","author":"Z Lv","year":"2020","unstructured":"Lv Z, Guo Y. Metformin and its benefits for various diseases. Front Endocrinol (Lausanne). 2020;11:191.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2643_CR10","doi-asserted-by":"publisher","first-page":"135","DOI":"10.3389\/fonc.2019.00135","volume":"9","author":"F Barbieri","year":"2019","unstructured":"Barbieri F, Verduci I, Carlini V, Zona G, Pagano A, Mazzanti M, et al. Repurposed biguanide drugs in glioblastoma exert antiproliferative effects via the inhibition of intracellular chloride channel 1 activity. Front Oncol. 2019;9:135.","journal-title":"Front Oncol"},{"issue":"9","key":"2643_CR11","doi-asserted-by":"publisher","first-page":"5003","DOI":"10.21873\/anticanres.12819","volume":"38","author":"MA Lea","year":"2018","unstructured":"Lea MA, Kim H, des BC. Effects of biguanides on growth and glycolysis of bladder and colon cancer cells. Anticancer Res. 2018;38(9):5003\u201311.","journal-title":"Anticancer Res"},{"issue":"2","key":"2643_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmc.2019.115258","volume":"28","author":"D Xiao","year":"2020","unstructured":"Xiao D, Lu Z, Wang Z, Zhou S, Cao M, Deng J, et al. Synthesis, biological evaluation and anti-proliferative mechanism of fluorine-containing proguanil derivatives. Bioorg Med Chem. 2020;28(2):115258.","journal-title":"Bioorg Med Chem"},{"issue":"23","key":"2643_CR13","doi-asserted-by":"publisher","first-page":"34084","DOI":"10.18632\/oncotarget.9122","volume":"7","author":"M Fiorillo","year":"2016","unstructured":"Fiorillo M, Lamb R, Tanowitz HB, Mutti L, Krstic-Demonacos M, Cappello AR, et al. Repurposing atovaquone: targeting mitochondrial complex III and OXPHOS to eradicate cancer stem cells. Oncotarget. 2016;7(23):34084\u201399.","journal-title":"Oncotarget."},{"key":"2643_CR14","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/978-1-59745-423-0_10","volume":"675","author":"A Ekbom","year":"2011","unstructured":"Ekbom A. The Swedish multi-generation register. Methods Mol Biol. 2011;675:215\u201320.","journal-title":"Methods Mol Biol"},{"issue":"1","key":"2643_CR15","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1053\/j.gastro.2017.09.009","volume":"154","author":"J Ji","year":"2018","unstructured":"Ji J, Sundquist J, Sundquist K. Cholera vaccine use is associated with a reduced risk of death in patients with colorectal cancer: a population-based study. Gastroenterology. 2018;154(1):86\u201392 e1.","journal-title":"Gastroenterology."},{"issue":"9927","key":"2643_CR16","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1016\/S0140-6736(13)61649-9","volume":"383","author":"H Brenner","year":"2014","unstructured":"Brenner H, Kloor M, Pox CP. Colorectal cancer. Lancet. 2014;383(9927):1490\u2013502.","journal-title":"Lancet."},{"issue":"6","key":"2643_CR17","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1093\/aje\/kwq433","volume":"173","author":"H Quan","year":"2011","unstructured":"Quan H, Li B, Couris CM, Fushimi K, Graham P, Hider P, et al. Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am J Epidemiol. 2011;173(6):676\u201382.","journal-title":"Am J Epidemiol"},{"issue":"2","key":"2643_CR18","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1007\/s13187-009-0024-y","volume":"25","author":"CC Chen","year":"2010","unstructured":"Chen CC, Basch CE, Yamada T. An evaluation of colonoscopy use: implications for health education. J Cancer Educ. 2010;25(2):160\u20135.","journal-title":"J Cancer Educ"},{"issue":"3","key":"2643_CR19","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/s10689-005-0657-x","volume":"4","author":"RA Kerber","year":"2005","unstructured":"Kerber RA, Neklason DW, Samowitz WS, Burt RW. Frequency of familial colon cancer and hereditary nonpolyposis colorectal cancer (Lynch syndrome) in a large population database. Familial Cancer. 2005;4(3):239\u201344.","journal-title":"Familial Cancer"},{"issue":"3","key":"2643_CR20","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1053\/j.gastro.2009.11.044","volume":"138","author":"DP Taylor","year":"2010","unstructured":"Taylor DP, Burt RW, Williams MS, Haug PJ, Cannon-Albright LA. Population-based family history-specific risks for colorectal cancer: a constellation approach. Gastroenterology. 2010;138(3):877\u201385.","journal-title":"Gastroenterology."},{"issue":"2","key":"2643_CR21","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.ejca.2005.09.023","volume":"42","author":"AS Butterworth","year":"2006","unstructured":"Butterworth AS, Higgins JP, Pharoah P. Relative and absolute risk of colorectal cancer for individuals with a family history: a meta-analysis. Eur J Cancer. 2006;42(2):216\u201327.","journal-title":"Eur J Cancer"},{"issue":"3","key":"2643_CR22","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.cmet.2020.06.019","volume":"32","author":"K Vasan","year":"2020","unstructured":"Vasan K, Werner M, Chandel NS. Mitochondrial metabolism as a target for cancer therapy. Cell Metab. 2020;32(3):341\u201352.","journal-title":"Cell Metab"},{"issue":"3","key":"2643_CR23","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1042\/BJ20140620","volume":"462","author":"HR Bridges","year":"2014","unstructured":"Bridges HR, Jones AJ, Pollak MN, Hirst J. Effects of metformin and other biguanides on oxidative phosphorylation in mitochondria. Biochem J. 2014;462(3):475\u201387.","journal-title":"Biochem J"},{"key":"2643_CR24","doi-asserted-by":"publisher","first-page":"12308","DOI":"10.1038\/ncomms12308","volume":"7","author":"TM Ashton","year":"2016","unstructured":"Ashton TM, Fokas E, Kunz-Schughart LA, Folkes LK, Anbalagan S, Huether M, et al. The anti-malarial atovaquone increases radiosensitivity by alleviating tumour hypoxia. Nat Commun. 2016;7:12308.","journal-title":"Nat Commun"},{"issue":"1093","key":"2643_CR25","doi-asserted-by":"crossref","first-page":"20170966","DOI":"10.1259\/bjr.20170966","volume":"92","author":"H Tharmalingham","year":"2019","unstructured":"Tharmalingham H, Hoskin P. Clinical trials targeting hypoxia. Br J Radiol. 2019;92(1093):20170966.","journal-title":"Br J Radiol"},{"issue":"4","key":"2643_CR26","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1016\/j.bbrc.2018.04.042","volume":"499","author":"S Tian","year":"2018","unstructured":"Tian S, Chen H, Tan W. Targeting mitochondrial respiration as a therapeutic strategy for cervical cancer. Biochem Biophys Res Commun. 2018;499(4):1019\u201324.","journal-title":"Biochem Biophys Res Commun"},{"issue":"4","key":"2643_CR27","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/s10863-018-9755-y","volume":"50","author":"Z Lv","year":"2018","unstructured":"Lv Z, Yan X, Lu L, Su C, He Y. Atovaquone enhances doxorubicin\u2019s efficacy via inhibiting mitochondrial respiration and STAT3 in aggressive thyroid cancer. J Bioenerg Biomembr. 2018;50(4):263\u201370.","journal-title":"J Bioenerg Biomembr"},{"issue":"9","key":"2643_CR28","doi-asserted-by":"publisher","DOI":"10.1002\/jbt.22195","volume":"32","author":"D Chen","year":"2018","unstructured":"Chen D, Sun X, Zhang X, Cao J. Targeting mitochondria by anthelmintic drug atovaquone sensitizes renal cell carcinoma to chemotherapy and immunotherapy. J Biochem Mol Toxicol. 2018;32(9):e22195.","journal-title":"J Biochem Mol Toxicol"},{"issue":"5","key":"2643_CR29","doi-asserted-by":"publisher","first-page":"361","DOI":"10.7326\/0003-4819-146-5-200703060-00008","volume":"146","author":"USPST Force","year":"2007","unstructured":"Force USPST. Routine aspirin or nonsteroidal anti-inflammatory drugs for the primary prevention of colorectal cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2007;146(5):361\u20134.","journal-title":"Ann Intern Med"},{"key":"2643_CR30","unstructured":"Dehmer SP, O'Keefe LR, Grossman ES, Maciosek MV. Aspirin use to prevent cardiovascular disease and colorectal cancer: an updated decision analysis for the U.S. Preventive Services Task Force. Rockville (MD): Agency for Healthcare Research and Quality (US). 2022. Report No.: 21-05283-EF-2."},{"issue":"2","key":"2643_CR31","doi-asserted-by":"publisher","first-page":"208","DOI":"10.4269\/ajtmh.2007.76.208","volume":"76","author":"AK Boggild","year":"2007","unstructured":"Boggild AK, Parise ME, Lewis LS, Kain KC. Atovaquone-proguanil: report from the CDC expert meeting on malaria chemoprophylaxis (II). Am J Trop Med Hyg. 2007;76(2):208\u201323.","journal-title":"Am J Trop Med Hyg"},{"issue":"1","key":"2643_CR32","doi-asserted-by":"publisher","first-page":"25","DOI":"10.2165\/00002018-200427010-00003","volume":"27","author":"WR Taylor","year":"2004","unstructured":"Taylor WR, White NJ. Antimalarial drug toxicity: a review. Drug Saf. 2004;27(1):25\u201361.","journal-title":"Drug Saf"},{"key":"2643_CR33","doi-asserted-by":"crossref","unstructured":"Abugroun A, Colina Garcia I, Ahmed F, Potts S, Flicker M. The first report of atovaquone\/proguanil-induced vanishing bile duct syndrome: case report and mini-review. Travel Med Infect Dis. 2019;32:101439.","DOI":"10.1016\/j.tmaid.2019.06.010"},{"issue":"4","key":"2643_CR34","doi-asserted-by":"publisher","first-page":"533","DOI":"10.4269\/ajtmh.1999.60.533","volume":"60","author":"S Looareesuwan","year":"1999","unstructured":"Looareesuwan S, Chulay JD, Canfield CJ, Hutchinson DB. Malarone (atovaquone and proguanil hydrochloride): a review of its clinical development for treatment of malaria. Malarone Clinical Trials Study Group. Am J Trop Med Hyg. 1999;60(4):533\u201341.","journal-title":"Am J Trop Med Hyg"}],"container-title":["BMC Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-022-02643-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12916-022-02643-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-022-02643-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,7]],"date-time":"2024-10-07T22:21:21Z","timestamp":1728339681000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedicine.biomedcentral.com\/articles\/10.1186\/s12916-022-02643-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,10]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["2643"],"URL":"https:\/\/doi.org\/10.1186\/s12916-022-02643-3","relation":{},"ISSN":["1741-7015"],"issn-type":[{"value":"1741-7015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,10]]},"assertion":[{"value":"5 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved on February 6, 2013, by the Regional Ethical Review Board in Lund (Dnr 2012\/795 and later amendments), Sweden.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"439"}}